GlassScriptPhysician profile
Mary T Abed
NPI 1134185432
$6,865.97
in general payments reported to CMS, 2019-2025
30 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $496 · 2021: $1,198 · 2022: $1,334 · 2023: $688 · 2024: $1,036 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553 · Education: $57.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.68 |
| Education | $57.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $900.44 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $692.25 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $665.07 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $594.77 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $495.77 | 2019-2022 | |
| Medtronic, INC. | $452.79 | 2021-2024 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.47 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $369.62 | 2019-2024 | Xarelto |
| Pfizer INC. | $303.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $295.07 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $204.70 | 2019-2025 | Avvigo Guidance System |
| Heartflow, INC. | $194.61 | 2024-2025 | |
| Abbott Laboratories | $179.41 | 2019-2022 | |
| Bridgebio Pharma, INC. | $168.85 | 2025 | Attruby |
| Novo Nordisk INC | $159.81 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $156.57 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $152.12 | 2019-2022 | |
| Amarin Pharma, INC. | $96.71 | 2019-2022 | |
| Medtronic Vascular, INC. | $76.17 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $42.81 | 2025 | Opsynvi |
| Zoll Circulation INC | $42.24 | 2022 | |
| Inari Medical, INC. | $35.00 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Esperion Therapeutics, INC. | $29.14 | 2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $27.91 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.97 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.08 | 2023 | Arcalyst |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $14.64 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $14.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Abed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.